The cardiovascular hemodynamics and leukotriene kinetics during prostacyclin and anti-prostacyclin antibody infusions in septic shock

Shock

Volumn 13, Issue 6, 2000, Pages 478-484

  Tran, Hoang S ^a   Quinn, James V ^a   Puc, Matthew M ^a   Woolley, Daniel S ^a   Puglisi, Roberto N ^a   Slotman, Gus J ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

Author keywords

Aeromonas hydrophila; Anti prostacyclin antibody; Cardiovascular hemodynamics; Gram negative bacteremia; Leukotriene B4; Leukotrienes C4D4E4; Porcine model; Prostacyclin; Septic shock

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTIBODY; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; PROSTACYCLIN; THROMBOXANE B2;

AEROMONAS HYDROPHILA; ANIMAL; ARTICLE; BACTEREMIA; BLOOD; COMPARATIVE STUDY; GRAM NEGATIVE INFECTION; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; SEPTIC SHOCK; SWINE;

6-KETOPROSTAGLANDIN F1 ALPHA; AEROMONAS HYDROPHILA; ANIMALS; ANTIBODIES; BACTEREMIA; EPOPROSTENOL; GRAM-NEGATIVE BACTERIAL INFECTIONS; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; SHOCK, SEPTIC; SWINE; THROMBOXANE B2;

EID: 0034200862     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200006000-00010     Document Type: Article

References (44)

1. Parrillo JE: Septic shock in humans: clinical evaluation, pathophysiology, and therapeutic approach. In Shoemaker WC, Thompson WL, Holbrook P (eds): Textbook of Critical Care. Philadelphia: W. B. Sauders, 1989, pp 1006-1023.
2. Parker MM, Parrillo JE: Septic shock, hemodynamics and pathogenesis: JAMA 250:3324-3327, 1983.
3. Parrillo JE. The cardiovascular response to human septic shock: In Fuhrman BP, Shoemaker WC (eds): Critical Care: State of the Art. Fullerton CA: Society of Critical Care Medicine, 1989, pp 285-314.
4. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parrillo JE: Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med 15: 923-929, 1987.
5. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321:280-287, 1989.
6. Helleyer PW, Johnson LW, Olson NC: Effect of N-nitro-L-arginine-methyl-ester on cardiopulmonary function and biosynthesis of cyclooxygenase products during porcine endotoxemia. Crit Care Med 25:1051-1058, 1997.
7. Slotman GJ, Machiedo GW, Casey KF, Lyons MJ: Histologic and hemodynamic effects of prostacyclin and prostaglandin E1 following oleic acid infusion. Surgery 92:93-99, 1982.
8. Slotman GJ, Quinn JV, Burchard KW, Gann DS: Thromboxane interaction with cardiopulmonary dysfunction in graded bacterial sepsis. J Trauma 24:803-810, 1984.
9. Slotman GJ, Quinn JV, Burchard KW, Gann DS: Thromboxane, prostacyclin, and the hemodynamic effects of graded bacteremic shock. Circ Shock: 16:395-404, 1985.
10. Slotman GJ, Burchard KW, Williams JJ, D'Arezzo A, Yellin SA: Interaction of prostagladins, activated complement, and granulocytes in clinical sepsis and hypotension. Surgery 99:744-750, 1986.
11. Slotman GJ, Teplitz C, Yellin SA, Farrugia R: Interarction of thromboxane A2 and tissue pathology during graded bacteremia. J Trauma 27:167-171, 1987.
12. Salartash K, Galluci J, J Quinn, Catalano E, Slotman G: The cardiopulmonary, eicosanoid, and tissue microanatomic effects of fluconazole during graded bacteremia. Shock 6: 206-212, 1996.
13. Oettinger W, Pfleiderer A, Heil K, Seifert J, Brendel W: Evaluation of endogenous and exogenous prostacyclin in a porcine endotoxin shock model. Eur Surg Res 14:112-113, 1982.
14. Carmona RH, Tsao TC, Trunkey DD: The role of prostacyclin and thromboxane in sepsis and septic shock. Arch Surg 119:189-192, 1984.
15. Utsunomiya T, Krauss MM, Kobayashi M, Shepro D, Hechtman HB: Myocardial protection with prostacyclin after lethal endotoxemia. Surgery 92:101-108, 1982.
16. Schneider J: Beneficial effects of the prostacyclin analogue taprostene on cardiovascular, pulmonary and renal disturbances in endotoxin-shocked rabbits. Eicosanoids 4:99-105, 1991.
17. Manasia A, Kang H, Hannon E, Lu Y, Oropello J, Leibwitz A, Stein J, Benjamin E: Effects of the stable prostacyclin analogue iloprost on mesenteric blood flow in porcine endotoxic shock. Crit Care Med 25:1222-1227, 1997.
18. Krausz MM, Utsunomiya T, Feuerstein G, Wolf JHN, Shepro D, Hechtman HB: Prostacyclin reversal of lethal endotoxemia in dogs. J Clin Invest 67:1118-1125, 1981.
19. Ditter H, Matthias FR, Voss R, Lohmann E: Beneficial effects of prostacyclin in a rabbit endotoxin shock model. Thromb Res 51: 403-415, 1988.
20. Fletcher JR, Ramwell PW: The effects of prostacyclin on endotoxin shock and endotoxin-induced platelet aggregation in dogs. Circ Shock 7:299-308, 1980.
21. Bihari DJ, Tinker J: The therapeutic value of vasodilator prostaglandins in multiple organ failure associated with sepsis. Intensive Care Med 15:2-7, 1988.
22. Oettinger W, Berger D, Beger HG: The clinical significance of prostaglandins and thromboxane as mediators of septic shock. Klin Wochenschr 65:61-68, 1987.
23. Fletcher JR, Collins JN, Graves ED, Luterman A, Williams MD, Izenberg SD, Rodning CB: Tumor necrosis factor-induced mortality is reversed with cyclooxygenase inhibition. Ann Surg 217:668-675, 1993.
24. Talmadge JE, Bowersox O, Tribble H, Lee SH, Shepard M, Liggitt D: Toxicity of tumor necrosis factor is synergistic with ?-interferon and can be reduced with cyclooxygenase inhibitors. Am J Pathol 128:410-425, 1987.
25. von Graevenitz A, Mensch AH: The genus aeromonas in human bacteriology. N Engl J Med 278:245-249, 1968.
26. Gallucci J, Quinn J, Seidel G, Slotman GJ: Fluconazole reduces oxygen utilization and maintains capillary integrity during bacteremia. Crit Care Med 22:A243, 1994.
27. Gallucci JC, Quinn JV, Woolley D, Seidel G, Slotman GJ: Prostacyclin mediates increased oxygen consumption and arterial hypoxemia, preserves cardiac index, and prevents platelet aggregation during graded bacteremia. In: Faist E, Baue AE, Schildberg FW (ed): MOF, MODS and SIRS -Concepts, Clinical Correlates and Therapy. Berlin FRG: Pabst Science Publishers, 1996, pp 1-5.
28. Steffen RP, de la Mata M: The effects of 15AU81, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensis systems of anesthetized dogs. Prostaglandins Leukotrienes and Essential Fatty Acids 43:277-286, 1991.
29. Rie M, Peterson M, Kong D, Quinn D, Watkins D: Plasma prostacyclin increases during acute human sepsis. Circ Shock 10:232, 1983.
30. Schneider J: Salutary effects of the prostacyclin analogue CG4203 in lethal endotoxemia in rats. Prostaglandins Leukotrienes and Essential Fatty Acids 31:139-146, 1988.
31. Reines HD, Cook JA, Haluska PV, Wise WC: Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 8291: 174-175, 1982.
32. Hedqvist P: Basic mechanism of prostaglandin action on autonomie neurotransmission. Ann Rev Pharmacol Toxicol 17:259-265, 1977.
33. Auinger G, Virgolini I, Weissel M, Bergmann H, Sinzinger H: Prostacyclin 12 increases left ventricular ejection fraction. Prostaglandins Leukotrienes and Essential Fatty Acids 36:149-154, 1989.
34. Elsner D, Kromer EP, Riegger GA: Hemodynamic, hormonal and renal effects of the prostacyclin analogue iloprost in conscious dogs with and without heart failure. J Cardiovasc Pharmacol 16:601-608, 1990.
35. 2+ and cyclic AMP in the regulation of the production of prostacyclin by the vascular endothelium. Proc Natl Acad Sci USA 79:495 -499, 1982.
36. Zimmerman GA, McIntyre TM, Prescott SM: Production of platelet-activating factor by human vascular endothelial cells. Evidence for a requirement for specific agonists and modulation by prostacyclin. Circulation 72:718-727, 1985.
37. Heller R, Bussolino F, Ghido D: Protein kinase C and cyclic AMP modulate thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochem Biophys Acta 1093:55-64, 1991.
38. Fuerstein G: Cardiac and vascular effects of leukotrienes. In: Zor U (ed): Advances in Prostaglandin, Tthromboxane and Leukotriene Research. New York: Raven Press, 1986, pp 299-308.
39. Krausz MM, Dahan JB, Gross D: Effect of the leukotriene receptor antagonist LY-171883 on endotoxemia in awake sheep. Circ Shock 26:431-441, 1988.
40. Tempel GE, Strong JW, Wise WC, Cook JA, Smith EF, Haluska PV. The role of eicosanoids in mediating blood flow alterations in endotoxin shock. Prog Clin Biol Res 299:33-42, 1989.
41. Lewis RA, Austen F, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645-655, 1990.
42. Rola-Pleszczynski M, Borgeat P, Sirois P: Leukotriene B4 induces human suppressor lymphocytes. Biochem Biophys Res Commun 108:1531-1537, 1982.
43. Rola-Pleszczynski M, Chavaillaz PA, Lemaire I: Stimulation of interleukin 2 and interferon gamma production by leukotriene B4 in human lymphocyte cultures. Prostaglandin Leukotrienes Med 23:207-10, 1986.
44. Rola-Pleszczynski M, Lemaire I: Leukotrienes augment interleukin I production by human monocytes. J Immunol 135:3958-3961, 1985.